Go Deep
ReproCELL Incorporated
ReproCELL Incorporated Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,483 | -25.8 | 1.32 | 0.00 | 73.85 |
| Oct 2026 | 20,334 | -27.6 | 1.37 | 0.00 | 76.73 |
ReproCELL Incorporated Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 546,699,000.0 | 623,729,000.0 | 635,724,000.0 | 498,220,000.0 |
| Net Profit | -149,503,000.0 | -132,791,000.0 | 27,439,000.0 | -182,020,000.0 |
| EPS | -1.6 | — | — | — |
ReproCELL Incorporated Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 2,233,518,000.0 | 2,978,627,000.0 | 2,426,817,000.0 | 2,953,271,000.0 | — |
| Net Profit | -591,693,000.0 | 103,245,000.0 | -31,415,000.0 | -305,313,000.0 | — |
| EPS | -6.2 | 1.1 | -0.4 | -3.6 | — |
ReproCELL Incorporated Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 9,052,627,000.0 | 9,670,755,000.0 | 9,052,627,000.0 | 8,355,848,000.0 | — |
| Total Liabilities | 741,034,000.0 | 685,809,000.0 | 741,034,000.0 | 780,625,000.0 | — |
| Total Equity | 8,311,593,000.0 | 8,984,946,000.0 | 8,311,593,000.0 | 7,575,223,000.0 | — |
Owes vs Owns
ReproCELL Incorporated owed ¥0.07 for every ¥1 it owned in Jun 2026, down from ¥0.09 in Mar 2023.
| Period | Jun 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.07× | 0.08× | 0.07× | 0.08× | 0.09× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
ReproCELL Incorporated Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 72.5%Receivables 4.7%Inventory 2.7%Fixed assets (tangible) 2.2%Long-term investments 15.3%Other assets 2.3%
How it's funded — Mar 2026
Payables 1.9%Other liabilities 6.3%Shareholders' equity 91.8%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 6,566.9 | 3,941.6 | 6,566.9 | 6,379.4 |
| Receivables | 421.3 | 463.9 | 421.3 | 445.8 |
| Inventory | 248.1 | 270.4 | 248.1 | 234.3 |
| Fixed assets (tangible) | 199.6 | 241.7 | 199.6 | 101.2 |
| Intangible assets | 24.2 | 26.8 | 24.2 | 15.0 |
| Long-term investments | 1,381.9 | 4,403.5 | 1,381.9 | 1,005.4 |
| Other assets | 210.6 | 322.8 | 210.6 | 174.8 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 170.1 | 131.1 | 170.1 | 207.0 |
| Other liabilities | 570.9 | 554.7 | 570.9 | 573.6 |
| Shareholders' equity | 8,311.6 | 8,984.9 | 8,311.6 | 7,575.2 |
| Net tangible assets | 8,287.4 | 8,958.1 | 8,287.4 | 7,560.3 |
ReproCELL Incorporated Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -383,526,000.0 | 6,287,000.0 | -11,451,000.0 | -140,534,000.0 | — |
| Investing Activities | 57,940,000.0 | -795,995,000.0 | 404,424,000.0 | -1,087,496,000.0 | — |
| Financing Activities | 0.0 | 680,110,000.0 | 544,050,000.0 | 482,872,000.0 | — |